Side-Effect Management Archives - Cancer Therapy Advisor

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

Novel Treatment Approach May Reduce Risk of Death From ICI-Related Myocarditis

By

March 3, 2023

A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.

Head and Neck Cancer

Turmeric Mouthwash Reduces Severity of Oral Mucositis in Head and Neck Cancer

By

Jennifer Larson

January 30, 2023

Researchers compared a turmeric mouthwash to benzydamine mouthwash in patients with head and neck cancer.

General Oncology

Duration of CINV During First Chemotherapy Cycle Predicts CINV Recurrence

By

Andrea S. Blevins Primeau, PhD, MBA

January 5, 2023

The occurrence and duration of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of chemotherapy predict CINV recurrence in later cycles, a study suggests.

Breast Cancer

Acupuncture Reduces Aromatase Inhibitor-Related Joint Pain in Breast Cancer Patients

November 15, 2022

Acupuncture can reduce aromatase inhibitor-related joint pain in women with early breast cancer, a study suggests.

General Oncology

New Guideline on Integrative Medicine for Pain Management in Oncology

By

Vicki Moore, PhD

October 11, 2022

ASCO and SIO issued a joint guideline on the use of integrative medicine for pain management in oncology.

Clinicians talking with an electronic health record showing on the screen

Lung Cancer

Real-World PRO Monitoring in Lung Cancer Lower Than in Clinical Trial Settings

By

Jessica Nye, PhD

October 5, 2022

Researchers sought to measure real-world adherence to patient-reported outcome monitoring as a cancer care metric.

General Oncology

Electronic PROs May Address Gap in Care for Patients With Limited English Proficiency

By

Jessica Nye, PhD

August 24, 2022

Patients with limited English proficiency taking oral cancer medications expressed interest in using language-adapted ePROs.

Bladder Cancer

Cutaneous Adverse Effects Common With Enfortumab Vedotin for Urothelial Cancer

By

Vicki Moore, PhD

March 23, 2022

Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.